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Meta-analysisAbstract Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme of folate/homo-
cysteine pathway and is essential for synthesis, repair and methylation of DNA. Various studies
have performed to evaluate the role ofMTHFR A1298C gene polymorphism to the risk of prostate
cancer and the results were inconclusive and inconsistent. A meta-analysis of published case-control
studies, up to December 2014, was performed to investigate the association between MTHFR
A1298C gene polymorphism and the susceptibility of prostate cancer. PubMed, Science direct,
Springer link and Google scholar databases were searched for case-control studies and crude odds
ratios (ORs) with 95% conﬁdence intervals (CIs) were calculated to estimate the strength of asso-
ciation. The analyses were conducted with Open Meta-Analyst and MIX softwares. Total thirteen
case-control studies with 4673 prostate cancer patients and 6982 controls were included in this
meta-analysis. No associations were observed between MTHFR A1298C gene polymorphism and
prostate cancer in any genetic model (allele contrast (C vs. A): OR = 1.01; 95% CI: 0.91–1.13;
p= 0.73; dominant model (CC + AC vs. AA): OR= 0.98, 95% CI = 0.91–1.06, p= 0.73;
homozygote model (CC vs. AA): OR = 0.96, 95% CI = 0.83–1.10, p= 0.55; co-dominant model
(AC vs. AA): OR= 0.98, 95% CI = 0.91–1.07, p= 0.76; and recessive model (CC vs. AC + AA):
OR = 0.96, 95% CI = 0.84–1.10, p= 0.61). Moreover, when the data were stratiﬁed on the basis
of ethnicity no signiﬁcant associations were observed. The results of the present meta-analysis sug-
gest that theMTHFR A1298C gene polymorphism has no effect on the etiology of prostate cancer.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Prostate cancer (PCa) is the second most common cancer in
men with an estimated 1.1 million new PCa cases and 0.30 mil-
lion deaths in 2012 [1]. The estimated age standardized rate for
PCa is 30.7 per 100,000 and it is more prevalent in developed
regions (68.0) then less developed regions (14.5) [1]. PCa is a
slow-growing cancer and remains localized at ﬁrst and later
due to the abnormal proliferation of prostatic tissue cells it
may extend as it spreads to nearby tissues and organs and then
metastasizes. Although it is one of the most common types of
cancer its causes are least understood. Several risk factors have
been reported for PCa like age, race, family history of cancer,
smoking, alcohol intake etc [2].
Genome–environment interaction and genetic susceptibility
were evaluated for cancer risk. Folic acid is essential for DNA
synthesis, repair and methylation and several studies reported
enzyme variants of folate–methionine pathway as risk
factor for carcinogenesis. Methylenetetrahydrofolate reductase
(MTHFR) plays an important role in the metabolism
of folic acid/homocysteine pathway by converting 5,10-
methylenetetrahydrofolate to 5-methylenetetrahydrofolate,
which donates a methyl group for remethylation of homocys-
teine to methionine [3].MTHFR gene has 11 exons and located
at chromosome 1p36.3. A number of SNPs are reported in this
gene. Clinically important one of them is A1298C (rs1801131)
which is located at exon 7 and results in a glutamate to alanine
substitution [4]. The frequency of mutant allele (C) greatly dif-
fers in different populations. The prevalence of the A1298C
homozygote genotype (CC) ranges from 1% to 4% in
Chinese, 4% to 5% in Hispanics, and 7% to 12% in North
American and European populations [5,6].
MTHFR A1298C gene polymorphism is associated with a
number of diseases like Down syndrome [7], schizophrenia
[8], neural tube defects [9], orofacial clefts [10], nonsyndromic
cleft lip and palate [11] etc. Contrary reports were published
regarding MTHFR polymorphism as a risk factor for cancer,
i.e. positive association [12] and negative association [13–15]have been continuously reported in different types of cancers.
MTHFR A1298C polymorphism has also been investigated to
assess the risk of PCa but the results were inconclusive [16–21].
These inconsistent results might be due to differences in ethnic-
ity, genotyping methods and small sample sizes in individual
studies. Hence we decided to carry out an updated meta-
analysis to shed some light on this controversial association.2. Materials and methods
2.1. Selection of studies
PubMed, Science direct, Springer link and Google scholar
databases were searched for ‘‘prostate cancer’’ with the combi-
nation of following keywords – ‘‘methylenetetrahydrofolate
reductase’’, ‘‘MTHFR’’, and ‘‘rs1801131’’. Included papers
were further searched manually for additional studies. The
databases were searched up to March, 2015.
2.2. Inclusion and exclusion criteria
The inclusion criteria were as follows – (i) published studies;
(ii) case-control study; (iii) distribution of genotypes in cases
and controls were reported in the publication. The following
exclusion criteria were studies – (i) not in English language;
(ii) that contained duplicate data; and (iii) case reports, letter
to editor, book chapters or reviews.
2.3. Data extraction
The following data were extracted from each study-year of
publication, ﬁrst author’s name, country of study, ethnicity,
and frequency of C allele in controls for detection of Hardy–
Weinberg equilibrium. The AA, AC and CC genotype num-
bers in the case and control groups were extracted from each
included study to calculate odds ratio (OR) and 95% conﬁ-
dence interval (95% CI).
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We calculated the pooled OR with 95% CI to investigate the
association between MTHFR A1298C gene polymorphism
and risk of PCa for the allele contrast (C vs. A), dominant
(CC and AC vs. AA), homozygote (CC vs. AA), co-
dominant (AC vs. AA), and recessive (CC vs. AC and AA)
models. The Q statistic was used to test for heterogeneity
(p< 0.05 was considered as statistically signiﬁcant heterogene-
ity) and I2 statistic was used to quantify the inconsistency
between study estimates. I2 ranges between 0% and 100%,
and I2 values of 25%, 50% and 75% were deﬁned as low, mod-
erate and high estimates of heterogeneity, respectively. When a
signiﬁcant Q-test (p< 0.05) or I2 > 50%, indicated hetero-
geneity across studies, the random effects model [22] was used
or else ﬁxed effects model was applied [23]. Subgroup analysis
was conducted on the basis of ethnicity. Publication bias was
assessed by the symmetry of the funnel plot. An asymmetrical
funnel plot suggested publication biasness. Funnel plot asym-
metry was further evaluated by the Egger’s linear regression
method [24]. Statistical analyses were done with Open Meta-
Analyst [25] and MIX 1.7 [26]. All p-values were two-tailed
with a signiﬁcance level at 0.05.Table 1 Characteristics of the eligible studies considered in the me
SN Author Ethnicity Cou
1 Cicek et al. (2004) Mixed USA
2 Singal et al. (2004) Mixed USA
3 Van Guelpen et al. (2006) Caucasian Swed
4 Marchal et al. (2008) Caucasian Spai
5 Stevens et al. (2008) Caucasian USA
6 Collin et al. (2009) Caucasian UK
7 Muslumanoglu et al. (2009) Caucasian Turk
8 Cai et al. (2010) Asian Chin
9 Safarinejad et al. (2010) Asian Iran
10 Wu et al., 2010 Asian Taiw
11 Vidal et al. (2012) Caucasian USA
12 Jackson et al. (2013) Mixed Wes
13 Lo´pez-Corte´s et al. (2013) Mixed Equ
Figure 1 Flow diagram of study search and selection process.3. Results
3.1. Eligible studies
Fig. 1 presents the ﬂow diagram of the retrieved studies and
the studies excluded, with specifying reasons and the informa-
tion extracted from the studies included in the meta-analysis is
provided in Table 1. On the basis of our predeﬁned eligibility
criteria thirteen studies were found eligible to include in this
meta-analysis [16–21,27–33] which consists of 4673 and 6982
cases and controls respectively.
3.2. Characteristics of included studies
Among the thirteen studies, three were from Asian populations
[18,19,32], ﬁve were form Caucasian populations [16,17,29–31],
and the remaining ﬁve were of mixed ethnicities
[20,21,27,28,33]. In thirteen studies included in the present
meta-analysis, the smallest case sample was 55 [33] and the
highest sample size was 1599 [17]. Control populations in all
the studies were in Hardy–Weinberg equilibrium except three
studies [20,21,31].
In all thirteen studies the numbers of cases were 4673 with
AA (2347), AC (1899), and CC (427) and controls were AA
(3,461), AC (2856), and CC (665). In cases the percentages
for genotypes were 50.22% for AA, 40.64% for AC and
9.14% for CC. Similarly for controls these values were
49.57%, 40.91% and 9.52% for AA, AC and CC genotype.
All included studies have sufﬁcient information to
calculate the ﬁve genetic models-allele contrast (C vs. A),
dominant (CC + AC vs. AA), homozygote (CC vs. AA),
co-dominant (AC vs. AA), and recessive (CC vs. AC + AA)
to evaluate A1298C polymorphism as PCa risk (Table 2).
3.3. Meta-analysis
Meta-analysis with allele contrast showed insigniﬁcant associ-
ation with random effect model (ORCvsA = 1.01; 95% CI:
0.91–1.13; p= 0.73; I2 = 54%; Pheterogeneity = 0.01) (Fig. 2).
Moderate heterogeneity was found so random effect model
was applied. Low heterogeneity was found in all the other four
genetic models, so ﬁxed effect model was applied. No associa-
tion between the MTHFR A1298C gene polymorphism andta-analysis.
ntry No. of controls No. of cases Years
479 439 2004
42 81 2004
en 617 299 2006
n 205 182 2008
1107 1100 2008
2084 1599 2009
ey 166 93 2009
a 220 217 2010
348 174 2010
an 436 218 2010
192 55 2012
t Indies 273 243 2013
ador 110 104 2013
Figure 2 Random effect Forest plot of allele contrast model (C vs. A) of MTHFR A1298C polymorphism.
Table 2 The distributions of MTHFR A1298C genotypes and allele frequencies for prostate cancer cases and controls.
Study ID Genotype Alleles HWE
AA AC CC A C
Case Control Case Control Case Control Case Control Case Control
Cicek et al. (2004) 195 233 205 201 39 44 595 667 283 289 0.94
Singal et al. (2004) 29 18 43 17 9 7 101 53 61 31 0.39
Van Guelpen et al. (2006) 87 176 108 203 27 55 282 555 162 313 0.76
Marchal et al. (2008) 98 108 62 79 17 22 258 295 96 123 0.19
Stevens et al. (2008) 481 491 518 493 105 125 1480 1475 728 743 0.94
Collin et al. (2009) 775 1407 673 1339 144 289 2223 4153 961 1917 0.24
Muslumanoglu et al. (2009) 31 77 16 45 44 44 78 199 104 133 0.00
Cai et al. (2010) 150 144 63 71 4 5 363 359 71 81 0.27
Safarinejad et al. (2010) 90 158 70 150 14 40 250 466 98 230 0.62
Wu et al. (2010) 138 287 70 135 10 14 346 709 90 163 0.69
Vidal et al. (2012) 36 103 17 79 2 11 89 285 21 101 0.40
Jackson et al. (2013) 137 151 52 43 10 8 326 345 72 59 0.03
Lopez-Cortes et al. (2013) 100 108 2 1 2 1 202 217 6 3 0.00
Total 2347 3461 1899 2856 427 665 6593 9778 2753 4186
Percentage 50.22 49.57 40.64 40.91 9.14 9.52
144 U. Yadav et al.PCa was found in any other genetic models (Table 3).
In homozygote model (CC vs. AA): OR= 0.96, 95%
CI = 0.83–1.10, p= 0.55 (Fig. 3); for dominant model
(CC + AC vs. AA) OR= 0.98, 95% CI = 0.91–1.06,
p= 0.73 (Fig. 4); for AC vs. AA (co-dominant model):
OR = 0.98, 95% CI = 0.91–1.07, p= 0.76; for CC vs.
AC + AA (recessive model): OR = 0.96 (95% CI = 0.84–
1.10, p= 0.61).
The sub-group analyses were conducted on the basis of eth-
nicity (Asian, Caucasian and Mixed). Low heterogeneity was
observed in Asian and mixed studies but high heterogeneity
was found in Caucasian studies. No signiﬁcant results were
found in any sub-group in any genetic models (Table 3).3.4. Sensitivity analyses
Sensitivity analysis was performed on the basis of deviation of
the control samples from HWE (p< 0.05). The control sam-
ples of three studies [20,21,31] were deviated from the HWE.
Sensitivity analysis was performed after removal of these stud-
ies and no signiﬁcant association was found in the main anal-
ysis (ORCvsA = 0.95; 95% CI: 0.90–1.01; p= 0.16; I
2 = 0%)
or in any sub-groups-Asian (ORCvsA = 0.92; 95% CI: 0.77–
1.09; p= 0.36; I2 = 36%); Caucasian (ORCvsA = 0.95; 95%
CI: 0.88–1.02; p= 0.17; I2 = 0%); and mixed (ORCvsA =
1.02; 95% CI: 0.86–1.22; p= 0.75; I2 = 34%). Moreover,
Table 3 Summary estimates for the odds ratio (OR) ofMTHFR A1298C in various allele/genotype contrasts, the signiﬁcance level (p
value) of heterogeneity test (Q test), and the I2 metric: overall analysis, and subgroup analyses.
Genetic contrast Fixed eﬀect Random eﬀect OR
(95% CI), p
Heterogeneity
p-value (Q test)
I2
(%)
Publication bias
(p of Egger’s test)
All (13 studies) Allele contrast (C vs. A) 0.98 (0.92–1.04), 0.62 1.01 (0.91–1.13), 0.73 0.01 54 0.3
Dominant (CC+ AC vs. AA) 0.98 (0.91–1.06), 0.73 1.00 (0.90–1.12), 0.86 0.15 28 0.29
Homozygote (CC vs. AA) 0.96 (0.83–1.10), 0.55 0.99 (0.82–1.19), 0.94 0.20 24 0.49
Co-dominant (AC vs. AA) 0.98 (0.91–1.07), 0.76 0.99 (0.91–1.07), 0.81 0.42 2 0.58
Recessive (AA+ AC vs. CC) 0.96 (0.84–1.10), 0.61 1.00 (0.82–1.22), 0.98 0.10 34 0.6
Asian (3 studies) Allele contrast (C vs. A) 0.92 (0.77–1.09), 0.36 0.92 (0.74–1.15), 0.47 0.20 36 0.9
Dominant (CC+ AC vs. AA) 0.91 (0.74–1.13), 0.40 0.91 (0.73–1.14), 0.43 0.32 11 0.52
Homozygote (CC vs. AA) 0.83 (0.51–1.34), 0.46 0.86 (0.48–1.55), 0.63 0.26 25 0.83
Co-dominant (AC vs. AA) 0.92 (0.73–1.14), 0.46 0.92 (0.74–1.14), 0.46 0.53 0 0.36
Recessive (AA+ AC vs. CC) 0.87 (0.54–1.39), 0.56 0.88 (0.54–1.44), 0.63 0.35 4 0.81
Caucasian
(5 studies)
Allele contrast (C vs. A) 0.97 (0.91–1.04), 0.52 1.04 (0.88–1.23), 0.57 0.003 75 0.26
Dominant (CC+ AC vs. AA) 0.96 (0.88–1.06), 0.50 0.99 (0.86–1.13), 0.93 0.18 35 0.26
Homozygote (CC vs. AA) 0.96 (0.82–1.12), 0.61 1.04 (0.77–1.41), 0.77 0.02 64 0.36
Co-dominant (AC vs. AA) 0.96 (0.87–1.06), 0.47 0.96 (0.87–1.06), 0.47 0.59 0 09
Recessive (AA+ AC vs. CC) 0.98 (0.84–1.13), 0.79 1.07 (0.77–1.48), 0.65 0.006 72 0.42
Mixed (5 studies) Allele contrast (C vs. A) 1.08 (0.92–1.26), 0.33 1.07 (0.87–1.32), 0.50 0.27 21 0.99
Dominant (CC+ AC vs. AA) 1.15 (0.94–1.40), 0.16 1.13 (0.86–1.49), 0.34 0.25 25 0.97
Homozygote (CC vs. AA) 1.03 (0.71–1.51), 0.84 1.04 (0.71–1.52), 0.82 0.79 0 0.9
Co-dominant (AC vs. AA) 1.17 (0.95–1.45), 0.13 1.16 (0.89–1.52), 0.26 0.29 19 0.99
Recessive (AA+ AC vs. CC) 0.94 (0.65–1.36), 0.77 0.94 (0.65–1.36), 0.77 0.79 0 0.96
Figure 3 Fixed effect Forest plot of homozygote model (CC vs. AA) of MTHFR A1298C polymorphism.
A1298C polymorphism and Prostate cancer risk 145when these studies (deviated from HWE) were removed from
the analysis then the between study heterogeneity decreases
both in the overall and sub-group meta-analysis.
3.5. Publication bias
The funnel plots are symmetrical for all genetic models in
either overall or sub-group meta-analyses. Moreover, Egger’stest reveals no evidence of publication bias in any genetic
model in both the main and sub-group meta-analysis (Fig. 5).
4. Discussion
MTHFR enzyme is crucial for folate metabolic pathway
because it is involved in two important pathways-DNA methy-
lation and purines and thymidine synthesis. MTHFR gene
Figure 4 Fixed effect Forest plot of homozygote model (CC + AC vs. AA) of MTHFR A1298C polymorphism.
Figure 5 Funnel plots of standard error by OR of MTHFR
A1298C allele contrast model (C vs. A).
146 U. Yadav et al.polymorphisms have been extensively studied as increased/re-
duced risk factor for different types of cancers and it was
observed that these polymorphisms increased the risk for
breast [34], cervical [35], and esophageal cancer [36] as well
as reduced the risk of colorectal cancer [37], non-Hodkin’s
lymphoma [38] and childhood acute leukemia [39]. MTHFR
gene polymorphisms confer increased/reduced risk of cancer
by two mechanisms, both mechanisms oppose one another.
Low activity of MTHFR variant enzyme causes DNA
hypomethylation and uracil misincorporation into DNA
[40,41]. These two events resulted into abnormal geneexpression, increased DNA break/damage and reduced DNA
repair and consequently increased risk of carcinogenesis. On
the other hand, reduced MTHFR activity increased the
availability of 5,10-methylenetetrahydrofolate which donates
the methyl group for the synthesis of deoxythymidylate
(dTMP) from deoxyuridylate (dUMP). Increased 5,10-
methylenetetrahydrofolate increased the synthesis of dTMP
and reduced incorporation of uridine in DNA and protects cell
against carcinogenesis [19,42].
During past decade several meta-analyses were published
assessingMTHFR A1298C gene polymorphism as a risk factor
to various diseases/disorders like NTD [43], recurrent preg-
nancy loss [44], Down syndrome [45], nonsyndromic cleft lip
and palate [46], and cancer [47,48] etc. Four meta-analyses
were published regarding MTHFR A1298C polymorphism
and PCa risk [17,47,49,50]. Bai et al. [49] performed a
meta-analysis with only four studies including 838 cases and
1121 controls and found no statistical signiﬁcant association.
In another meta-analysis published in the same year Collin
et al. [17] reported no association of MTHFR A1298C gene
polymorphism with PCa. This meta-analysis included 5 studies
comprising 3176 cases and 4829 controls. Out of the 5
studies three were Caucasian and two were of mixed ethnicity.
The major limitation of both these meta-analyses was that
they included only Caucasian and mixed ethnicity samples as
up to 2010 no study was published from the Asian population.
In a recent meta-analysis performed by Li et al. [47] a total of
nine case-control studies were included consisting of 2723
cases and 3442 controls. Out of nine studies four were
from Caucasians, three from mixed and two from Asian
ethnicities but they did not ﬁnd any statistically signiﬁcant
association. No association was found in another study pub-
lished in 2012 by Li and Xu [50] with the same papers as in
Li et al. [47].
The last meta-analyses were published in 2012 after that
several case-control studies were published. These studies were
A1298C polymorphism and Prostate cancer risk 147not included in the previous meta-analyses. So we conducted a
comprehensive meta-analysis with the largest number of stud-
ies (13 studies) and the highest number of samples (11,655) to
date to investigate the possible association between MTHFR
A1298C polymorphism and the risk of PCa. No statistically
signiﬁcant association was observed in either main analysis
or sub-group analysis which was based on ethnicity. The
results of the present meta-analysis support the results of the
previous meta-analyses that MTHFR A1298C gene polymor-
phism has no role in the etiology of PCa. Also on the stratiﬁ-
cation of data on the basis of ethnicity, no signiﬁcant
association was observed between the MTHFR A1298C gene
polymorphism and PCa either in overall or in any sub-group
(Asian, Caucasian or mixed) populations.
The main strengths of our meta-analysis were absence of
publication bias and pooled number of cases and controls
from different studies which signiﬁcantly increased the power
of the study. Present meta-analysis also has some limitations
which must be acknowledged like – (i) crude odds ratio was
used, (ii) meta-analysis was restricted to only one polymor-
phism (A1298C), and (iii) except genetic polymorphism other
important environmental factors were not considered.
5. Conclusion
In conclusion, the present study did not support any associa-
tion between MTHFR A1298C gene polymorphism and PCa
in total and stratiﬁed populations. For future case-control
studies gene–gene and gene–environment interactions should
also be considered which might well elucidate genetics of PCa.Conﬂict of interest
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